Heimberger says the treatment paradigm's future is two-pronged, in that it will consist of both combination therapies that activate the immune system and prevent immunosuppression, as well as understand CT and MRI scans of brain cancer patients.
Amy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, discusses the future of treatment for glioblastoma multiforme (GBM). Heimberger says the treatment paradigm's future is two-pronged, in that it will consist of both combination therapies that activate the immune system and prevent immunosuppression, as well as understand CT and MRI scans of brain cancer patients.